Program

5:00 pm

GEORG DUDA | BERLIN INSTITUTE OF HEALTH (BIH) | CHARITÉ – UNIVERSITÄTSMEDIZIN BERLIN

ORLA SMITH | SCIENCE TRANSLATIONAL MEDICINE

5:05 pm

AXEL RADLACH PRIES | DEAN, CHARITÉ – UNIVERSITÄTSMEDIZIN BERLIN

CHRISTOPHER BAUM | CEO, BERLIN INSTITUTE OF HEALTH (BIH)

5:10 pm

MODERATOR GEORG DUDA | BERLIN INSTITUTE OF HEALTH (BIH) | CHARITÉ – UNIVERSITÄTSMEDIZIN BERLIN 
Co-MODERATOR: C. CZAJKA | SCIENCE TRANSLATIONAL MEDICINE

Are translational research hubs allowed to pursue their translational opportunities freely? What does this control matrix look like? If de-risking occurs, what risks are considered moving from bench to bedside? What is the culture of project prioritization and selection? How are pet projects and politics avoided? Listen to experiences from large translational science oriented institutions

Angelika Fretzen | Wyss Institute at Harvard University
How to Gate Translational Progress?

Robert Guldberg | University of Oregon
Building a Culture that Promotes and Accelerates Translation

Louise Jones | Medical Research Council
Assessing Translational Progress within Peer Review Processes

Hildegard Büning | Hannover Medical School (MHH)
How can Translational Research be Empowered?

6:00 pm

MODERATOR: CAITLIN CZAJKA | SCIENCE TRANSLATIONAL MEDICINE
Co-MODERATOR: G. DUDA | BERLIN INSTITUTE OF HEALTH (BIH) | CHARITÉ – UNIVERSITÄTSMEDIZIN BERLIN 

Society is now being tapped to provide new real-world data, often in real time. Massive collections of personalized health data by wearables are increasing. But, who vets the quality of data collected en masse? How are such vast datasets collected, curated, and managed in the cloud? How will all of this be verified and protected to be used appropriately and remain traceable? Many published preclinical and clinical studies lack reproducibility and consistency in their messaging. How does the biomedical research enterprise enhance credibility and data veracity in both fundamental and translational forums? Experts will describe the current issues, policies and procedures with stewarding massive medical data sets and better reproducing biomedical studies to improve reliability.

Jennifer Goldsack | Digital Medicine Society (DiME)
Data Governance and Privacy in the Age of Digital Medicine

Christof von Kalle | Berlin Institute of Health (BIH) | Charité – Universitätsmedizin Berlin
How to Boost Translation by Data Sciences – Cancer as a Role Model?

Christine Manta | Elektra Labs
Digital Medicine, Biomarkers, Diagnostics, and Therapeutics

Andrew Morris | The University of Edinburgh
Maintaining the Integrity of a Trustworthy Health Data Ecosystem

6:55 pm

MODERATOR: ORLA SMITH | SCIENCE TRANSLATIONAL MEDICINE
Co-MODERATOR: J. SCHULZ | RWTH AACHEN

Common metrics used to assess real world translational success include impact factors, publications and patents for academics, and product launch, marketing and publicity for industry. Many national funding incentives use performance leveraged budgeting (e.g., impact factors or publication production based research awards). Synergies between basic and translational science are often advocated as essential, but how much rote discovery/serendipity “blue-sky” fundamental research is proper? How much risk is allocated to translational-oriented research? How are real world translational research efforts ranked and assessed to ensure high quality global translational sciences? Are Translational Readiness Levels a solution? What benchmarks for success are appropriate?

Hans-Dieter Volk |  Berlin Institute of Health (BIH) | Charité – Universitätsmedizin Berlin
Translational Readiness Levels – a Feasible Strategy To Judge on Progress?

Hans-Gustaf Ljunggren | Karolinska Institute
The Value of Creating Well-Organized Biobanks for Translational Research: The Karolinska COVID-19 Case

Jeffrey Bluestone | The University of California, San Francisco (UCSF)
Challenges of Rewarding Entrepreneurship in Translational Academic Research

7:50 – 8:10 pm

Report on Consensus Process I 
Measuring Translation – What Works, What Does Not?

Contribute to a conference consensus statement to guidance on metrics that better inform translational progress and rank success.

Glenn Prestwich | Washington State University

Hans-Dieter Volk | Berlin Institute of Health (BIH) | Charité – Universitätsmedizin Berlin

Brenna Rauw | 12Bridge LLC, Portland

8:10 – 8:30 pm

Report on Consensus Process II
The Role of Data Reproducibility in Translation

Contribute to a conference consensus statement on improving biomedical data stewardship, veracity, validation and confidence, and how this might be enforced to improve translational efficiency.

Ronenn Roubenoff | Novartis Institutes for Biomedical Research

Ulrich Dirnagl | Berlin Institute of Health (BIH) | Charité – Universitätsmedizin Berlin

Petra Reinke | Berlin Institute of Health (BIH) | Charité – Universitätsmedizin Berlin

8:35 pm

KLAUS NITSCHKE | BERLIN INSTITUTE OF HEALTH (BIH)

8:50 pm

GEORG DUDA | BERLIN INSTITUTE OF HEALTH (BIH) | CHARITÉ – UNIVERSITÄTSMEDIZIN BERLIN

5:00 pm

DAVID GRAINGER | UNIVERSITY OF UTAH

5:05 – 5:40 pm

BRUCE J. TROMBERG | NATIONAL INSTITUTE OF HEALTH (NIH)

5:40 pm

MODERATOR: DAVID GRAINGER | UNIVERSITY OF UTAH
Co-MODERATOR: O. SMITH | SCIENCE TRANSLATIONAL MEDICINE

Regulatory agencies can enforce new regulations in unpredictable ways, creating risks in translation. Globalization of regulatory policy is inconsistent and defaults to country-specific enforcement. Regulatory sciences are now being developed to produce quantitative research specific to regulatory requirements. Other developments (adaptive clinical trial designs, digital twins, Nobel Prizes) are changing translational perspectives and approval opportunities. Experts present models, metrics and experiences for translating biomedical products in different global environments.

Setsuko Hashimoto | CellSeed Inc.
Accelerating Translational Research in Advanced Technologies

Andrew Carr | University of Oxford
New Approaches to Value-Driven Device Developments

Stefan Schreck | DG SANTE C European Commission
From Creating New Knowledge To Its Application: A New Approach at EU Level

Caroline Paunov | Organization for Economic Co-Operation and Development (OECD)
Inclusive Innovation in the Digital Age and University-Industry Collaboration in Innovation

6:30 pm

MODERATOR: JÖRG SCHULZ | RWTH AACHEN
Co-MODERATOR: HD. VOLK | BERLIN INSTITUTE OF HEALTH (BIH) | CHARITÉ – UNIVERSITÄTSMEDIZIN BERLIN
Academic cultures and structures are seen to both limit and boost translation – often steering innovation from the bottom up through a labyrinth of barriers inconsistent with translation. New translationally oriented institutes are now acting independently of their academic hosts (e.g. Zuckerberg/Stanford; Gladstones/PICI/UCSF) whereas others are enabled by their institutional directives (e.g. Mayo Clinics, Scripps Institutes). How much entrepreneurial excellence, innovation and translation can be expected in modern academic settings? Can they evolve?

Susanne Herold | University Hospital of Gießen and Marburg (UKGM)

Translation in Times of COVID-19 – and Beyond

Andre Terzic |  Mayo Clinic
Practice-Centric Translation Strategy

Stephen Kern | Bill and Melinda Gates Foundation
Essential Characteristics for Effective Translational Research

Wolfgang Wick | Heidelberg University Hospital
Neurooncology – Translating Novel Concepts Into Clinical Application

7:25 pm

MODERATOR: HANS-DIETER VOLK | BERLIN INSTITUTE OF HEALTH (BIH) | CHARITÉ – UNIVERSITÄTSMEDIZIN BERLIN
Co-MODERATOR: G. DUDA | BERLIN INSTITUTE OF HEALTH (BIH) | CHARITÉ – UNIVERSITÄTSMEDIZIN BERLIN

Many global regulatory agencies have recently developed fast-track approval processes in response to clinical needs, commercial demands, and researcher inputs. Can this same strategy be further adapted for more general approaches to biomedical translation?

Zami Aberman | Pluristem Therapeutics Inc.
Allogeneic “Living Drugs” Treatments: Translation From Acute (Muscle) Injury and Chronic Ischemia to Treatment of Acute Respiratory Distress Syndrome (ARDS) Resulting From COVID-19.

Peter Marks | U.S. Food and Drug Administration (FDA)
Accelerated Product Development and Approval

Katja Brose | Chan Zuckerberg Initiative
A Basic Science Perspective on Translational Challenges in Times of Global Challenges

Klaus Cichutek | Paul-Ehrlich-Institute (PEI)
Accelerated Approval Process in Times of Crises

8:15 pm

Discussion on Consensus Paper Draft I

Refine the conference consensus statement for guidance on metrics that better inform translational progress and rank success.

Glenn Prestwich | Washington State University

Hans-Dieter Volk | Berlin Institute of Health (BIH) | Charité – Universitätsmedizin Berlin

Brenna Rauw | 12Bridge LLC, Portland

8:35 pm

Discussion on Consensus Paper Draft II

Refine the conference consensus statement on improving biomedical data stewardship, veracity, validation and confidence, and how this might be enforced to improve translational efficiency.

Ronenn Roubenoff | Novartis Institutes for Biomedical Research

Ulrich Dirnagl | Berlin Institute of Health (BIH) | Charité – Universitätsmedizin Berlin

Petra Reinke | Berlin Institute of Health (BIH) | Charité – Universitätsmedizin Berlin

8:55 pm

PitchCAITLIN CZAJKA | SCIENCE TRANSLATIONAL MEDICINE

GEORG DUDA | BERLIN INSTITUTE OF HEALTH (BIH) | CHARITÉ – UNIVERSITÄTSMEDIZIN BERLIN